CJC-1295 NO DAC

CJC-1295 NO DAC (Modified GRF 1–29) is a synthetic 29-amino-acid GHRH analog designed to stimulate pulsatile growth hormone secretion from the pituitary gland while preserving the body's physiologic feedback loop.

Profile · 01

Overview

CJC-1295 NO DAC (Modified GRF 1–29) is a synthetic 29-amino-acid GHRH analog designed to stimulate pulsatile growth hormone secretion from the pituitary gland while preserving the body's physiologic feedback loop. It features four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that enhance stability against enzymatic degradation. It is not FDA-approved for any indication.

Clinical studies demonstrate dose-dependent GH and IGF-1 elevation, and its short half-life (~30 minutes) produces discrete GH pulses that mimic the body's natural secretion pattern. This protocol presents a once-daily subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal
Stimulate pulsatile GH release and elevate IGF-1 levels to support body composition, recovery, and metabolic health
Categories
Growth Hormone OptimizationBody CompositionRecoveryAnti-Aging
Synergistic
Ipamorelin · CJC-1295 DAC · GHRP-6 · GHRP-2
Profile · 02

Protocol

Suggested daily titration approach starting low and increasing every one to two weeks.

Typical daily range
100–300 mcg once daily (gradual titration)
Start
100–150 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated
Target
200–300 mcg daily by Weeks 5–12
Frequency
Once per day (subcutaneous), preferably at bedtime
Cycle Length
8–12 weeks; optional extension to 16 weeks
Timing
Administer at bedtime to align with natural nocturnal GH pulses; rotate injection sites
Route
Subcutaneous
Cycle
8–12 weeks on, 4 weeks off

Inject once daily subcutaneously at bedtime to align with natural nocturnal GH pulsatility. Administer on an empty stomach (fasted at least 2 hours) to optimize GH response. For injections at or below 10 units (Weeks 1–4), consider 30- or 50-unit insulin syringes for improved readability. The short half-life produces discrete GH pulses that mimic natural secretion, unlike the sustained release of the DAC variant.

Dose progression

Weeks 1–2
100 mcg (0.1 mg)
Weeks 3–4
150 mcg (0.15 mg)
Weeks 5–6
200 mcg (0.2 mg)
Weeks 7–12
250–300 mcg (0.25–0.3 mg)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How CJC-1295 NO DAC works.

CJC-1295 NO DAC (Modified GRF 1–29) is a truncated GHRH analog with four amino acid substitutions that enhance stability against enzymatic degradation. It binds to GHRH receptors on pituitary somatotrophs, stimulating synthesis and pulsatile endogenous GH release. Unlike exogenous GH administration, this preserves physiologic feedback loops, resulting in more natural GH pulsatility. The short half-life (~30 minutes) produces discrete GH pulses that mimic the body's natural secretion pattern. Clinical studies in healthy adults have demonstrated prolonged stimulation of GH and IGF-1 levels, and animal models confirm normalization of growth in GHRH-deficient models.

Science · 02

Effects

Observations from clinical or preclinical literature.

Stimulates pulsatile GH release and elevates IGF-1 levels with chronic administration (clinical data)
May support improvements in body composition, including increased lean mass and reduced fat mass
May enhance recovery, sleep quality, and overall energy levels
Preserves natural physiologic GH feedback loops unlike exogenous GH administration
Generally well tolerated in clinical and preclinical studies
Occasional mild side effects include injection-site reactions (redness, swelling), transient flushing, or headache
Long-term human safety and efficacy data remain limited
Science · 03

Caution

Individuals with active cancer or a history of cancer should avoid use due to GH/IGF-1 elevation and potential tumor-promoting effects
Not recommended during pregnancy or breastfeeding (no safety data available)
Use with caution in individuals with diabetes or insulin resistance, as GH elevation may affect glucose metabolism
Administer on an empty stomach (fasted at least 2 hours) to optimize GH response
Consult a healthcare provider before use if you have any chronic medical conditions

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Zinc
Supports immune function and is involved in GH signaling pathways.
Magnesium
Supports enzymatic processes and sleep quality, both relevant to GH optimization.
Vitamin D
Plays a role in hormonal regulation and overall metabolic health.
B Vitamins
Support energy metabolism and cellular processes that complement GH activity.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Pair with a balanced, protein-forward diet tailored to energy and recovery needs
Combine resistance training and aerobic activity to reinforce metabolic adaptations and GH response
Prioritize sleep and stress management to support natural GH pulsatility and recovery
Administer peptide in a fasted state to maximize GH release
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Body composition (lean mass, body fat percentage) — monitor changes to gauge response over the cycle
  2. Recovery quality and exercise performance — track workout capacity and post-exercise recovery times
  3. Sleep quality and duration — poor sleep impairs GH release; track to ensure adequate rest
  4. Injection-site reactions — note any redness, swelling, or discomfort to guide site rotation
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

IGF-1
Primary marker of GH axis stimulation; track before and during protocol.
Fasting Glucose and HbA1c
Monitor for GH-related effects on insulin sensitivity.
CBC (Complete Blood Count)
Monitor overall health and rule out underlying conditions.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
Thyroid Panel (TSH, Free T3, Free T4)
GH can influence thyroid hormone metabolism.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to dry
Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy
Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
Inject slowly; wait a few seconds before withdrawing the needle
Document daily dose and site rotation to maintain consistency
Administer on an empty stomach (fasted at least 2 hours) to optimize GH response
CJC-1295 NO DAC human data are from short-term clinical trials; clinical decisions should involve qualified healthcare providers
Reference · 02

References

  1. Wikipedia
    "Modified GRF (1–29): structure, amino acid substitutions, and pharmacokinetics".
    https://en.wikipedia.org/wiki/CJC-1295
  2. J Clin Endocrinol Metab (2006)
    Teichman SL et al., "Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults".
    https://pubmed.ncbi.nlm.nih.gov/16352683/
  3. Am J Physiol (2006)
    Alba M et al., "Once-daily CJC-1295 normalizes growth in GHRH knockout mice".
    https://pubmed.ncbi.nlm.nih.gov/16822960/
  4. J Clin Endocrinol Metab (2006)
    Veldhuis JD et al., "Pulsatile GH secretion persists during continuous CJC-1295 stimulation".
    https://pubmed.ncbi.nlm.nih.gov/17018654/
  5. PMC
    "Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels".
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675260/
  6. PMC
    "Effects of GHRH Analog (Tesamorelin) on Endogenous GH Pulsatility and Insulin Sensitivity".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC3038486/
  7. PMC
    "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
  8. PMC
    "Beyond the androgen receptor: role of GHS in body composition in hypogonadal males".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/
  9. PMC
    "The Safety and Efficacy of Growth Hormone Secretagogues (Review)".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/
  10. PMC
    "GHRH Effects on Brain GABA Levels in Mild Cognitive Impairment and Healthy Aging".
    https://ncbi.nlm.nih.gov/pmc/articles/PMC3764915
  11. PubMed
    "Sermorelin: review of its use in diagnosis and treatment of GH deficiency".
    https://pubmed.ncbi.nlm.nih.gov/18031173/
  12. CDC
    "Vaccine administration: subcutaneous route (angle/site; no aspiration)".
    https://www.cdc.gov/vaccines/hcp/administration/during.html
  13. CDC
    "Technique diagram and site guidance for subcutaneous injections".
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  14. NCBI Bookshelf
    "Best practices for injection (asepsis, preparation, and administration)".
    https://www.ncbi.nlm.nih.gov/books/NBK138495/
  15. Subcutaneous Drug Injection Review (PMC)
    "Pharmacologic considerations of the subcutaneous route".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
  16. Pure Lab Peptides
    "CJC-1295 NO DAC (5 mg) product page (quality and batch documentation)".
    https://purelabpeptides.com/buy-peptides/buy-cjc-1295-no-dac-5mg/
On this page